This Viewpoint uses examples of recommendations for race-based pharmacogenetic testing to discuss flaws and inconsistencies with race and ethnicity as surrogates for biology, and the consequences of those deficiencies for clinical decision-making.
No takes yet. Share an insight, caveat, or question.
Goodman et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: